08:00 , Nov 13, 2014 |  BC Innovations  |  Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

FluGEM: Phase I data

A single-blind, Dutch Phase I trial in 60 healthy volunteers aged 18-49 showed that intranasal FluGEM was well tolerated with a rate of overall adverse events comparable to that of standard trivalent split influenza antigen....
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

Mucosis preclinical data

In mice, Mucosis' FluGEM vaccine provided full protection against homologous and heterologous influenza infection, with a 300-fold reduction in viral titers in the lungs vs. conventional influenza vaccination. Data were published in Vaccine. FluGEM is...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Clinical News

FluGEM: Phase I started

Mucosis began a single-blind, placebo-controlled, Dutch Phase I trial to evaluate intranasal and intramuscular injections of FluGEM in 90 healthy adults ages 18-49. After an interim safety analysis, the company said the trial may be...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Company News

Mucosis, TNO infectious news

TNO will develop methods for selecting, formulating and manufacturing linker molecules to attach influenza antigens to Mucosis' Mimopath delivery system. The government R&D organization will provide €1.2 million ($1.6 million) to support the work. The...